Global Urinary Tract Infection Treatment Market to Reach $12.7 Billion by 2030
The global market for Urinary Tract Infection Treatment estimated at US$10.5 Billion in the year 2022, is projected to reach a revised size of US$12.7 Billion by 2030, growing at a CAGR of 2.4% over the analysis period 2022-2030. Quinolones, one of the segments analyzed in the report, is projected to record 2.3% CAGR and reach US$5.2 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the ß-lactam segment is readjusted to a revised 3.1% CAGR for the next 8-year period.The U.S. Market is Estimated at $2.9 Billion, While China is Forecast to Grow at 3.8% CAGR
The Urinary Tract Infection Treatment market in the U.S. is estimated at US$2.9 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$2.4 Billion by the year 2030 trailing a CAGR of 3.8% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 1.6% and 2.1% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 1.9% CAGR.Select Competitors (Total 41 Featured) -
- Allergan PLC
- AstraZeneca PLC
- Bayer AG
- Johnson & Johnson
- Lipella Pharmaceuticals Inc.
- Merck & Co., Inc.
- MerLion Pharmaceuticals GmbH
- Mylan Pharmaceutical Pvt. Ltd.
- Novartis AG
- Novo Nordisk A/S
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- Urigen Pharmaceuticals, Inc.
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and the publisher's Research Platform
- Complimentary updates for one year
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERSIV. COMPETITION
1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Impact of Covid-19 and a Looming Global Recession
- Urinary Tract Infection Treatment - Global Key Competitors Percentage Market Share in 2020 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2020 (E)
4. GLOBAL MARKET PERSPECTIVE
- Table 1: World Recent Past, Current & Future Analysis for Urinary Tract Infection Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 2: World Historic Review for Urinary Tract Infection Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 3: World 16-Year Perspective for Urinary Tract Infection Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2023 & 2030
- Table 4: World Recent Past, Current & Future Analysis for Quinolones by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 5: World Historic Review for Quinolones by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 6: World 16-Year Perspective for Quinolones by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
- Table 7: World Recent Past, Current & Future Analysis for Aminoglycosides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 8: World Historic Review for Aminoglycosides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 9: World 16-Year Perspective for Aminoglycosides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
- Table 10: World Recent Past, Current & Future Analysis for ß-lactam by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 11: World Historic Review for ß-lactam by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 12: World 16-Year Perspective for ß-lactam by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
- Table 13: World Recent Past, Current & Future Analysis for Other Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 14: World Historic Review for Other Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 15: World 16-Year Perspective for Other Segments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
- Table 16: World Urinary Tract Infection Treatment Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
- Table 17: World Recent Past, Current & Future Analysis for Penicillin & Combinations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 18: World Historic Review for Penicillin & Combinations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 19: World 16-Year Perspective for Penicillin & Combinations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
III. MARKET ANALYSIS
- UNITED STATES
- Urinary Tract Infection Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
- Table 20: USA Recent Past, Current & Future Analysis for Urinary Tract Infection Treatment by Segment - Quinolones, ß-lactam, Penicillin & Combinations, Aminoglycosides and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 21: USA Historic Review for Urinary Tract Infection Treatment by Segment - Quinolones, ß-lactam, Penicillin & Combinations, Aminoglycosides and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 22: USA 16-Year Perspective for Urinary Tract Infection Treatment by Segment - Percentage Breakdown of Value Sales for Quinolones, ß-lactam, Penicillin & Combinations, Aminoglycosides and Other Segments for the Years 2014, 2023 & 2030
- CANADA
- Table 23: Canada Recent Past, Current & Future Analysis for Urinary Tract Infection Treatment by Segment - Quinolones, ß-lactam, Penicillin & Combinations, Aminoglycosides and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 24: Canada Historic Review for Urinary Tract Infection Treatment by Segment - Quinolones, ß-lactam, Penicillin & Combinations, Aminoglycosides and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 25: Canada 16-Year Perspective for Urinary Tract Infection Treatment by Segment - Percentage Breakdown of Value Sales for Quinolones, ß-lactam, Penicillin & Combinations, Aminoglycosides and Other Segments for the Years 2014, 2023 & 2030
- JAPAN
- Urinary Tract Infection Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
- Table 26: Japan Recent Past, Current & Future Analysis for Urinary Tract Infection Treatment by Segment - Quinolones, ß-lactam, Penicillin & Combinations, Aminoglycosides and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 27: Japan Historic Review for Urinary Tract Infection Treatment by Segment - Quinolones, ß-lactam, Penicillin & Combinations, Aminoglycosides and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 28: Japan 16-Year Perspective for Urinary Tract Infection Treatment by Segment - Percentage Breakdown of Value Sales for Quinolones, ß-lactam, Penicillin & Combinations, Aminoglycosides and Other Segments for the Years 2014, 2023 & 2030
- CHINA
- Urinary Tract Infection Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
- Table 29: China Recent Past, Current & Future Analysis for Urinary Tract Infection Treatment by Segment - Quinolones, ß-lactam, Penicillin & Combinations, Aminoglycosides and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 30: China Historic Review for Urinary Tract Infection Treatment by Segment - Quinolones, ß-lactam, Penicillin & Combinations, Aminoglycosides and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 31: China 16-Year Perspective for Urinary Tract Infection Treatment by Segment - Percentage Breakdown of Value Sales for Quinolones, ß-lactam, Penicillin & Combinations, Aminoglycosides and Other Segments for the Years 2014, 2023 & 2030
- EUROPE
- Urinary Tract Infection Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
- Table 32: Europe Recent Past, Current & Future Analysis for Urinary Tract Infection Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 33: Europe Historic Review for Urinary Tract Infection Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 34: Europe 16-Year Perspective for Urinary Tract Infection Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2023 & 2030
- Table 35: Europe Recent Past, Current & Future Analysis for Urinary Tract Infection Treatment by Segment - Quinolones, ß-lactam, Penicillin & Combinations, Aminoglycosides and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 36: Europe Historic Review for Urinary Tract Infection Treatment by Segment - Quinolones, ß-lactam, Penicillin & Combinations, Aminoglycosides and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 37: Europe 16-Year Perspective for Urinary Tract Infection Treatment by Segment - Percentage Breakdown of Value Sales for Quinolones, ß-lactam, Penicillin & Combinations, Aminoglycosides and Other Segments for the Years 2014, 2023 & 2030
- FRANCE
- Urinary Tract Infection Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
- Table 38: France Recent Past, Current & Future Analysis for Urinary Tract Infection Treatment by Segment - Quinolones, ß-lactam, Penicillin & Combinations, Aminoglycosides and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 39: France Historic Review for Urinary Tract Infection Treatment by Segment - Quinolones, ß-lactam, Penicillin & Combinations, Aminoglycosides and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 40: France 16-Year Perspective for Urinary Tract Infection Treatment by Segment - Percentage Breakdown of Value Sales for Quinolones, ß-lactam, Penicillin & Combinations, Aminoglycosides and Other Segments for the Years 2014, 2023 & 2030
- GERMANY
- Urinary Tract Infection Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
- Table 41: Germany Recent Past, Current & Future Analysis for Urinary Tract Infection Treatment by Segment - Quinolones, ß-lactam, Penicillin & Combinations, Aminoglycosides and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 42: Germany Historic Review for Urinary Tract Infection Treatment by Segment - Quinolones, ß-lactam, Penicillin & Combinations, Aminoglycosides and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 43: Germany 16-Year Perspective for Urinary Tract Infection Treatment by Segment - Percentage Breakdown of Value Sales for Quinolones, ß-lactam, Penicillin & Combinations, Aminoglycosides and Other Segments for the Years 2014, 2023 & 2030
- ITALY
- Table 44: Italy Recent Past, Current & Future Analysis for Urinary Tract Infection Treatment by Segment - Quinolones, ß-lactam, Penicillin & Combinations, Aminoglycosides and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 45: Italy Historic Review for Urinary Tract Infection Treatment by Segment - Quinolones, ß-lactam, Penicillin & Combinations, Aminoglycosides and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 46: Italy 16-Year Perspective for Urinary Tract Infection Treatment by Segment - Percentage Breakdown of Value Sales for Quinolones, ß-lactam, Penicillin & Combinations, Aminoglycosides and Other Segments for the Years 2014, 2023 & 2030
- UNITED KINGDOM
- Urinary Tract Infection Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
- Table 47: UK Recent Past, Current & Future Analysis for Urinary Tract Infection Treatment by Segment - Quinolones, ß-lactam, Penicillin & Combinations, Aminoglycosides and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 48: UK Historic Review for Urinary Tract Infection Treatment by Segment - Quinolones, ß-lactam, Penicillin & Combinations, Aminoglycosides and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 49: UK 16-Year Perspective for Urinary Tract Infection Treatment by Segment - Percentage Breakdown of Value Sales for Quinolones, ß-lactam, Penicillin & Combinations, Aminoglycosides and Other Segments for the Years 2014, 2023 & 2030
- SPAIN
- Table 50: Spain Recent Past, Current & Future Analysis for Urinary Tract Infection Treatment by Segment - Quinolones, ß-lactam, Penicillin & Combinations, Aminoglycosides and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 51: Spain Historic Review for Urinary Tract Infection Treatment by Segment - Quinolones, ß-lactam, Penicillin & Combinations, Aminoglycosides and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 52: Spain 16-Year Perspective for Urinary Tract Infection Treatment by Segment - Percentage Breakdown of Value Sales for Quinolones, ß-lactam, Penicillin & Combinations, Aminoglycosides and Other Segments for the Years 2014, 2023 & 2030
- RUSSIA
- Table 53: Russia Recent Past, Current & Future Analysis for Urinary Tract Infection Treatment by Segment - Quinolones, ß-lactam, Penicillin & Combinations, Aminoglycosides and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 54: Russia Historic Review for Urinary Tract Infection Treatment by Segment - Quinolones, ß-lactam, Penicillin & Combinations, Aminoglycosides and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 55: Russia 16-Year Perspective for Urinary Tract Infection Treatment by Segment - Percentage Breakdown of Value Sales for Quinolones, ß-lactam, Penicillin & Combinations, Aminoglycosides and Other Segments for the Years 2014, 2023 & 2030
- REST OF EUROPE
- Table 56: Rest of Europe Recent Past, Current & Future Analysis for Urinary Tract Infection Treatment by Segment - Quinolones, ß-lactam, Penicillin & Combinations, Aminoglycosides and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 57: Rest of Europe Historic Review for Urinary Tract Infection Treatment by Segment - Quinolones, ß-lactam, Penicillin & Combinations, Aminoglycosides and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 58: Rest of Europe 16-Year Perspective for Urinary Tract Infection Treatment by Segment - Percentage Breakdown of Value Sales for Quinolones, ß-lactam, Penicillin & Combinations, Aminoglycosides and Other Segments for the Years 2014, 2023 & 2030
- ASIA-PACIFIC
- Urinary Tract Infection Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
- Table 59: Asia-Pacific Recent Past, Current & Future Analysis for Urinary Tract Infection Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 60: Asia-Pacific Historic Review for Urinary Tract Infection Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 61: Asia-Pacific 16-Year Perspective for Urinary Tract Infection Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2023 & 2030
- Table 62: Asia-Pacific Recent Past, Current & Future Analysis for Urinary Tract Infection Treatment by Segment - Quinolones, ß-lactam, Penicillin & Combinations, Aminoglycosides and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 63: Asia-Pacific Historic Review for Urinary Tract Infection Treatment by Segment - Quinolones, ß-lactam, Penicillin & Combinations, Aminoglycosides and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 64: Asia-Pacific 16-Year Perspective for Urinary Tract Infection Treatment by Segment - Percentage Breakdown of Value Sales for Quinolones, ß-lactam, Penicillin & Combinations, Aminoglycosides and Other Segments for the Years 2014, 2023 & 2030
- AUSTRALIA
- Urinary Tract Infection Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
- INDIA
- Urinary Tract Infection Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
- SOUTH KOREA
- REST OF ASIA-PACIFIC
- LATIN AMERICA
- Urinary Tract Infection Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
- ARGENTINA
- BRAZIL
- MEXICO
- REST OF LATIN AMERICA
- MIDDLE EAST
- Urinary Tract Infection Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
- IRAN
- ISRAEL
- SAUDI ARABIA
- UNITED ARAB EMIRATES
- REST OF MIDDLE EAST
- AFRICA
- Urinary Tract Infection Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Allergan PLC
- AstraZeneca PLC
- Bayer AG
- Johnson & Johnson
- Lipella Pharmaceuticals Inc.
- Merck & Co., Inc.
- MerLion Pharmaceuticals GmbH
- Mylan Pharmaceutical Pvt. Ltd.
- Novartis AG
- Novo Nordisk A/S
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- Urigen Pharmaceuticals, Inc.
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 194 |
Published | April 2024 |
Forecast Period | 2022 - 2030 |
Estimated Market Value ( USD | $ 10.5 Billion |
Forecasted Market Value ( USD | $ 12.7 Billion |
Compound Annual Growth Rate | 2.4% |
Regions Covered | Global |